Is Sartorius Stedim Biotech S.A. a good investment? Sartorius Stedim Biotech S.A. (SDMHF) is currently trading at 217.09 USD.
In terms of valuation, the stock trades at a P/E ratio of 61.67. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Sartorius Stedim Biotech S.A. is expected to release its next earnings report on Oct. 22, 2026.
For income investors, Sartorius Stedim Biotech S.A. pays a dividend yield of 0.37%. With a payout ratio of 23%, the dividend appears sustainable.
Yes, it pays an annual dividend of 0.80 USD (0.37% yield).
Sartorius Stedim Biotech S.A. is classified as a Stock. You can compare it against 5 other assets in the "Related Symbols" list on this page.
The next earnings date is projected to be Oct. 22, 2026. The company currently has a trailing EPS of 3.52.
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
| Year | Total Dividends |
|---|---|
| ▸2027 |
0.90 USD
|
| April 5, 2027 (estimated) | 0.8998 |
| ▸2026 |
0.80 USD
|
| April 2, 2026 | 0.8014 |
| ▸2025 |
0.76 USD
|
| April 4, 2025 | 0.7625 |
| ▸2024 |
0.74 USD
|
| April 4, 2024 | 0.7431 |
| ▸2023 |
1.57 USD
|
| April 3, 2023 | 1.5693 |
| ▸2022 |
1.40 USD
|
| April 4, 2022 | 1.3977 |
| ▸2021 |
0.80 USD
|
| March 31, 2021 | 0.8009 |
| ▸2020 |
0.38 USD
|
| July 1, 2020 | 0.3820 |
| ▸2019 |
0.64 USD
|
| April 2, 2019 | 0.6400 |
| ▸2018 |
0.57 USD
|
| April 11, 2018 | 0.5667 |
| ▸2017 |
0.45 USD
|
| April 11, 2017 | 0.4458 |
| ▸2016 |
2.26 USD
|
| April 15, 2016 | 2.2559 |
| ▸2015 |
1.38 USD
|
| April 14, 2015 | 1.3776 |
| ▸2014 |
1.67 USD
|
| April 15, 2014 | 1.6670 |
| ▸2013 |
1.45 USD
|
| April 19, 2013 | 1.4454 |
| ▸2012 |
1.31 USD
|
| April 20, 2012 | 1.3122 |
| ▸2011 |
1.32 USD
|
| April 29, 2011 | 1.3162 |
| ▸2010 |
0.79 USD
|
| April 30, 2010 | 0.7938 |
| ▸2009 |
0.39 USD
|
| April 30, 2009 | 0.3939 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Sartorius Stedim Biotech S.A. | Apr 02, 2026 | Paid | 0.8014 USD |
| Split Date | Split Ratio to 1 |
|---|---|
| May 6, 2016 | 6:1 |
Community Discussion